Historical Stock Chart
3 Months : From Sep 2019 to Dec 2019
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration approved one of its respiratory medicines as a self-administered and pre-filled syringe called the Fasenra pen.
Fasenra, a treatment for severe eosinophilic asthma, can now be used by patients themselves as an injection administered once every eight weeks. The pharmaceutical company said that this allows for more convenient dosing at home.
Fasenra was already approved in the U.S., as well as Europe and Japan as a drug given by doctors.
Write to Carlo Martuscelli at email@example.com
(END) Dow Jones Newswires
October 04, 2019 02:28 ET (06:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.